Impact of Normalisation of Haemostasis for People with Haemophilia A - European Medical Journal

Impact of Normalisation of Haemostasis for People with Haemophilia A

Hematology

Highlights from Sobi EHA 2024 Non-promotional Symposium

This content is the summary report of a non-promotional symposium both funded by Sobi. The presentations and discussion reflect the personal views of the speaker and may not represent those of Sobi.

Read the summary report here.


Faculty:

Cédric Hermans (Chair)
Professor and Head of the Division of Adult Haematology, the Haemostasis and Thrombosis Unit, and the Haemophilia Centre, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Maria Elisa Mancuso
Senior Haematology Consultant, Centre for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Research Hospital & Humanitas University, Rozzano, Milan, Italy

Rubén Berrueco
Head of the Paediatric Haematology Department, Hospital Sant Joan de Déu, Barcelona, Spain; Institut de Recerca Sant Joan de Déu de Barcelona (IRSJD), Barcelona, Spain

Prescribing information may vary depending on local approval in each country. Before prescribing any product, always refer to the local materials such as the prescribing information and/or summary of product characteristics.

Job Code: NP-35966
Date of Prep: July 2024

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.